You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort
  1. Seung Won Lee1,
  2. Jee Myung Yang2,
  3. In Kyung Yoo3,
  4. Sung Yong Moon1,
  5. Eun Kyo Ha4,
  6. Abdullah Özgür Yeniova5,
  7. Joo Young Cho3,
  8. Min Seo Kim6,
  9. Jae Il Shin7,
  10. Dong Keon Yon8,9
  1. 1 Department of Data Science, Sejong University, Seoul, Korea (the Republic of)
  2. 2 Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (the Republic of)
  3. 3 Department of Gastroenterology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)
  4. 4 Department of Pediatrics, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea (the Republic of)
  5. 5 Division of Gastroenterology, Department of Internal Medicine, Tokat Gaziosmanpaşa University Faculty of Medicine, Tokat, Turkey
  6. 6 Genomics and Digital Health, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, Korea (the Republic of)
  7. 7 Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
  8. 8 Department of Pediatrics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea (the Republic of)
  9. 9 Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
  1. Correspondence to Dr. Dong Keon Yon, Seoul National University College of Medicine, Seoul 03080, Korea (the Republic of); yonkkang{at}gmail.com

https://doi.org/10.1136/gutjnl-2020-323672

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We appreciate the comment and discussion from Dr Roulet1 on our original article.2 The author criticised that (1) our study did not consider the dose-dependent exposure to proton pump inhibitors (PPIs); (2) our study did not investigate the relationship of PPI use in hospitalised patients with COVID-19 during treatment for COVID-19 and (3) although our study accounted for protopathic bias by excluding new non-steroidal anti-inflammatory drug users, protopathic bias occurred in patients who responded to the early digestive symptoms of COVID-19. We acknowledge that plausible academic concerns have been raised, which might improve the original discussion and extend the insight into the association between PPI usage and COVID-19.1 We have performed a post-hoc analysis from the Korean nationwide cohort, addressing these concern.

    Data were obtained from the Korean nationwide cohort study, which includes patients (≥18 years) who underwent SARS-CoV-2 testing between 1 January and 15 May 2020.2–4 We performed propensity score matching between current PPI users (prehospitalisation PPI usage) and non-users among patients with laboratory-confirmed COVID-19 (n=4785), as previously described.2 Posthospitalisation PPI usage was defined as in-hospital PPI use in general wards, not intensive care units. The outcomes were a composite endpoint 1 (requirement of oxygen therapy, intensive care unit admission, administration of invasive ventilation or death) and a composite endpoint …

    View Full Text